IGC Pharma, Inc. — Form 10-Q summary
Reporting period: Fiscal third quarter and nine months ended December 31, 2023; fiscal year ends March 31. Dollar amounts below are in U.S. dollars; financial statement amounts are in thousands unless noted.
Business context
IGC is a clinical-stage pharmaceutical company focused on Alzheimer’s disease and related conditions. Its lead candidate, IGC-AD1, is in a Phase 2B trial for agitation associated with Alzheimer’s dementia. The company also sells women’s wellness products and white-label formulations, and operates an infrastructure business involving construction contracts and equipment rentals.
Financial performance
| Metric | Three months ended Dec. 31, 2023 | Three months ended Dec. 31, 2022 | Nine months ended Dec. 31, 2023 | Nine months ended Dec. 31, 2022 |
|---|---|---|---|---|
| Revenue | $204 | $332 | $1,050 | $745 |
| Gross profit | $133 | $102 | $562 | $379 |
| Gross margin | 65% | 31% | 54% | 51% |
| Operating loss | $(2,998) | $(2,278) | $(7,628) | $(7,532) |
| Net loss | $(5,589) | $(2,249) | $(10,115) | $(7,476) |
| Basic and diluted loss per share | $(0.09) | $(0.04) | $(0.18) | $(0.14) |
Quarterly revenue fell 38%, while nine-month revenue rose 41%. The nine-month increase was mainly from white-label services; quarterly revenue was primarily Life Sciences. Gross margin improved, though management cautions that margins fluctuate with product mix and revenue is insufficient to project them reliably. Quarterly SG&A increased 42% to $2.228 million, which the company attributed mainly to one-time non-cash expenses. Nine-month R&D was $2.918 million, down 2%; quarterly R&D rose 12% to $903,000.
The quarter included a $2.623 million impairment of Nagpur, India land, reducing its carrying value from approximately $4.1 million to $1.4 million. The impairment contributed to the higher quarterly and nine-month net losses. The company also reported $746,000 of inventory write-offs for the nine months, primarily related to expiration, idle facility costs, freight, scrap, and spoilage, compared with $110,000 in the prior-year period.
Cash, liquidity and debt
- Cash and cash equivalents were $1.378 million at December 31, 2023, down from $3.196 million at March 31, 2023. Working capital was $1.647 million, versus $4.568 million.
- Net cash used in operating activities for the nine months was $4.673 million, compared with $5.530 million in the prior-year period. Investing activities provided $6,000; financing activities provided $2.857 million, primarily from common-stock issuance.
- Total liabilities were $2.206 million, including $1.936 million of current liabilities. Long-term loans were $138,000, principally an SBA disaster loan; the filing reports no material long-term debt.
- A credit agreement allows borrowing of up to $12 million, matures June 30, 2024, and has a renewal option. No amount had been drawn as of December 31. The company also entered into an agreement permitting common-stock sales of up to $60 million, subject to limitations.
- Management expects cash and the working-capital credit facility to support operations beyond the twelve months following issuance of the financial statements, but notes estimates may prove incorrect. The company expects continued operating losses and negative operating cash flows and may seek further financing, which could dilute shareholders.
Outlook, risks and other material items
- Management identifies clinical-trial outcomes as a primary driver of future success and expects R&D spending to increase as the IGC-AD1 Phase 2B trial and work on other Alzheimer’s candidates progress. The trial is designed for 146 participants; the filing reports 13 contracted U.S. and Canadian sites but does not provide a clear enrollment or completion estimate.
- The company’s nearer-term commercial focus is white-label services and Holief wellness products; it provides no quantitative revenue or earnings guidance. FDA approval, trial results, commercialization, intellectual-property protection, and regulatory treatment of hemp-based products remain significant uncertainties.
- The company added risks concerning AI initiatives, including implementation, regulatory, privacy, cybersecurity, intellectual-property, and reputational risks. It also disclosed risks from disposing of non-core assets, including potential sale prices below carrying value and ongoing holding costs.
- Claims receivable were $946,000; management said collection within the next 12 months would be challenging because of collection proceedings. The filing reports no material legal proceedings as of December 31. A dispute with Apogee was settled during the quarter; IGC paid $100,000 as part of a mutual release.
- Common shares outstanding increased from 53.077 million at March 31 to 63.734 million at December 31. The filing also reports approximately 9 million potentially dilutive securities excluded from loss-per-share calculations as anti-dilutive.
- Management concluded disclosure controls were effective and reported no material change in internal control over financial reporting during the quarter.
Key facts for investors to verify
- Current cash burn, available borrowing capacity and whether the company can secure additional funding on acceptable terms.
- Actual Phase 2B enrollment, trial milestones, results timing and the cash required to complete the study.
- Use and potential dilution from the $60 million stock-sale program, plus vesting and issuance of restricted stock units.
- Recoverability of the $946,000 claims receivable and realizable value of non-core assets following the Nagpur land impairment.
- Inventory quality and the causes of recurring write-offs, alongside the sustainability of product revenue and gross margins.